Comparison of Remifentanil and Dexmedetomidine for Monitored Anaesthesia Care During Vertebroplasty and Kyphoplasty

• Status: Completed
• Trial end date: 2014-10-01
• Target enrollment: 0
• Participant gender: All

Summary

This randomised, double-blind study compared remifentanil and dexmedetomidine for monitored anaesthesia care (MAC) during minimally invasive corrections of vertebral compression fracture (vertebroplasty (VP) and kyphoplasty (KP)).

In total, 80 ASA physical status I-III patients scheduled for VP and KP randomly received remifentanil or dexmedetomidine to maintain OAA/S scale ≤ 4 during the procedures. Multiple hemodynamic variables of patients were recorded and the frequency of oxygen desaturation, respiratory depression, intraoperative need for other opioids, recovery time, operator satisfaction score, and patients' overall pain experiences were also compared.

The investigators are expecting that both remifentanil and dexmedetomidine appear to be quite safe for MAC during VP and KP. Thus, dexmedetomidine may be an alternative for MAC during VP and KP in elderly patients.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Hallym University Medical Center
• Treatments: Adrenergic Agonists; Anesthetics; Dexmedetomidine; Ephedrine; Midazolam; Propofol; Pseudoephedrine; Remifentanil

Criteria

Inclusion Criteria:

• patients who are scheduled for vertebroplasty or kyphoplasty under monitored anesthesia care

• ASA status I-III

• aged more than 65 years old.

Exclusion Criteria:

• obesity (BMI > 30 kg/m2)

• hypotension (systolic blood pressure < 100 mmHg)

• bradycardia (heart rate < 60 bpm)

• heart block

• baseline oxygen desaturation (SpO2 < 90%)

• sleep apnea

• asthma, or chronic obstructive pulmonary disease

• those who refused to give informed consent